Biote corp.

biote Corp. Up to 72,069,990 Shares of Class A Common Stock . Up to 67,856,462 Shares of Class A Common Stock . Up to 5,566,666 Warrants. This prospectus supplement supplements the prospectus dated July 19, 2022 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-265714), as amended.

Biote corp. Things To Know About Biote corp.

Corporate Profile. Biote operates a high growth, differentiated medical practice-building business within the hormone optimization space. Similar to a franchise model, Biote provides the necessary components to enable practitioners to establish, build, and successfully operate a hormone optimization center to treat patients appropriate for therapy.WHO IS BIOTE? Biote is a leading innovator in precision and preventive medicine. For patients, it is a way for them to take control of their health through hormone optimization. For providers, it’s a way to learn how to identify and address the earliest indicators of aging.* A certain stockholder of biote Corp., a Delaware corporation (the “Company”) named in Schedule II attached hereto (the “Selling Stockholder”), propose, subject to the terms and conditions herein, to sell 5,217,392 shares (the “Firm Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”).Aug 24, 2022 · August 24, 2022 08:30 AM Eastern Daylight Time. IRVING, Texas-- ( BUSINESS WIRE )-- biote Corp. (“Biote” or the “Company”), a high growth, differentiated medical practice-building business ...

Stock analysis for Biote Corp (BTMD:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Biote-certified practitioners and Biote-partnered clinics are concentrated in certain geographic regions, which makes us sensitive to regulatory, economic, environmental and competitive conditions in those regions; •. The frequency of use by practitioners and clinics of the Biote Method may not increase at the rate that we anticipate or at ...

Biote Corp. Consolidated Balance Sheets (In Thousands) (Unaudited) September 30, December 31, 2023 2022 Assets: Current assets: Cash and cash equivalents $ 65,575 $ 79,231 Short-term investment ...

Biote Corp. Consolidated Statements of Operations (In Thousands, except per share values) (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2023. 2022. 2023. 2022. Revenue: Product ...IRVING, Texas -- (BUSINESS WIRE)--Nov. 7, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Debby Morris to Biote’s Board of Directors. Ms. Morris brings more than three decades of ...Nov 7, 2023 · Item 2.02. Results of Operations and Financial Condition. On November 7, 2023, biote Corp., a Delaware corporation (the “Company”) issued a press release to report the Company’s financial results for the quarter ended September 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Biote derives revenues by contractually sharing in the profit generated by Biote-certified practitioners and through the sale of its Biote-branded nutraceutical products. Biote-certified practitioners deliver personalized hormone replacement therapy to relieve the symptoms of hormonal imbalance, which affects approximately 200 million Americans.

Biote is the nation's largest hormone optimization company and one of the only companies actively contributing to furthering the science behind hormone ...

Biote Corp. Consolidated Statements of Operations (In Thousands, except per share values) (Unaudited) Three Months Ended March 31, 2023. 2022. Revenue: Product revenue $ 44,155 $ 36,758. Service ...

IRVING, Texas -- (BUSINESS WIRE)--Nov. 7, 2023-- Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of …biote Corp. (BTMD) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 5.24 +0.08 (+1.55%) At close: 01:00PM EST SummaryIRVING, Texas -- (BUSINESS WIRE)--Nov. 7, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Debby Morris to Biote’s Board of Directors. Ms. Morris brings more than three decades of ...Track biote Corp (BTMD) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable ...Nov 7, 2023 · Item 2.02. Results of Operations and Financial Condition. On November 7, 2023, biote Corp., a Delaware corporation (the “Company”) issued a press release to report the Company’s financial results for the quarter ended September 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Oct 24, 2023 ... IRVING, Texas--(BUSINESS WIRE)-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, today ...

Dec 1, 2023 · Stock analysis for Biote Corp (BTMD:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. View the latest Biote Corp. (BTMD) stock price, news, historical charts, analyst ratings and financial information from WSJ.Terry S. Weber. Age : 69. Public asset : 12,276,454 USD. Linked companies : biote Corp. Summary. Presently, Terry S. Weber is Chief Executive Officer & Director at biote Corp. and Chief Executive Officer & Director at Biote Medical LLC (a subsidiary of biote Corp.). She is also Partner at Mattioli Weber Consulting.IRVING, Texas-- ( BUSINESS WIRE )--biote Corp., (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building …IRVING, Texas--(BUSINESS WIRE)--Feb. 9, 2023-- Biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide fourth quarter and full year financial results on Tuesday, March 28, 2023, after the close of the market.May 31, 2022 · Biote Corp. biote Corp. provides precision and preventive medicines. The Company offers hormone therapy and products that boosts energy and immune system. biote serves customers worldwide.

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize …

Ms. Puncochar to Drive Execution of Biote’s Strategic Sales and Marketing Initiatives. IRVING, Texas--(BUSINESS WIRE)--May 30, 2023-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced the appointment …Optimize your hormones to help optimize your well-being. Every person is unique, and so are their hormones. Biote believes in personalized care, helping deliver a personalized …Biote Q4 Earnings Conference Call. March 29, 2023. Click here for webcast. Fourth Quarter and Full Year 2022 Earnings Call Transcript.biote Corp's stock price closed at $5.81. It is up 3.57% in the last 3 months and up 45.80% in the last 12 months. biote Corp saw positive EPS revisions and negative EPS revisions in the last 90 days. See biote Corp's stock price’s past reactions to earnings here. According to InvestingPro, biote Corp's Financial Health score is "great ...IRVING, TX, December 13, 2021 — BioTE Holdings, LLC, (Biote), a high-growth, differentiated medical practice-building business within the hormone optimization space (“Biote”), and Haymaker Acquisition Corp. III (Nasdaq: HYAC) (“Haymaker”), a special purpose acquisition company, today announced that they have entered into a definitive business combination agreement.Aug 9, 2022 · On June 5, 2023, biote Corp. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Roth Capital Partners, LLC, as the underwriter (the “Underwriter”), and a selling stockholder (the “Selling Stockholder”), in connection with the offering and sale (the “Offering”) by the Selling Stockholder of 5,217,392 shares (the “shares”) of Class ... Biote Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 May. 09: CI Certain Restricted Stock Units of biote Corp. are subject to a Lock-Up Agreement Ending on 6-APR-2023. Apr. 05: CI Certain Stock Options of biote Corp. are subject to a Lock-Up Agreement Ending on 6-APR-2023.

Biote Corp. Consolidated Balance Sheets (In Thousands) (Unaudited) September 30, December 31, 2023 2022 Assets: Current assets: Cash and cash equivalents $ 65,575 $ 79,231 Short-term investment ...

About Biote. Founded in 2012, Biote has experience phenomenal growth over the last decade. The Biote state-of-the-art training facility hosts physicians, healthcare providers, and medical staff members monthly during the Biote Method learning and certification process. To date, more than 6,400 medical practitioners have successfully completed ...

IRVING, Texas--(BUSINESS WIRE)--Apr. 26, 2023-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide first quarter financial results on Tuesday, May 9, 2023, after the close of the market.A …Exhibit 99.1 . Biote Appoints Samar Kamdar as Chief Financial Officer . IRVING, TX, August 24, 2022 — biote Corp. (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has appointed Samar Kamdar as its Chief Financial Officer. Mr. Kamdar will oversee …View the latest Biote Corp. (BTMD) stock price, news, historical charts, analyst ratings and financial information from WSJ.In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Common Stock, par value $0.0001 per share, of biote Corp., a Delaware corporation.A certain stockholder of biote Corp., a Delaware corporation (the “Company”) named in Schedule II attached hereto (the “Selling Stockholder”), propose, subject to the terms and conditions herein, to sell 5,217,392 shares (the “Firm Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”).IRVING, Texas, October 24, 2023--biote Corp. (Nasdaq: BTMD) ("Biote" or the "Company"), a leading provider of hormone optimization, today announced the Company will provide third quarter financial ...Get the latest biote Corp (BTMD) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.biote Corp’s Stock Price as of Market Close. As of November 08, 2023, 4:00 PM, CST, biote Corp’s stock price was $4.43. biote Corp is down 23.75% from its previous closing price of $5.81. During the last market session, biote Corp’s stock traded between $5.60 and $5.81. Currently, there are 20.70 million shares of biote Corp stock ...Biote Method to be available in IMAC outpatient medical clinics . IRVING, Texas--(BUSINESS WIRE)--Sep. 7, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has entered into a partnership with …

IRVING, Texas--(BUSINESS WIRE)--May 9, 2023-- Biote (NASDAQ: BTMD) (the “Company,” “we” or “us”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that it has commenced an exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its (i) 8,397,624 outstanding ...BioTE® optimizes hormone levels with tiny pellets just under the skin. Hormone pellets release bio-identical hormones into the bloodstream continuously. After ...Biote Corp. (NASDAQ:BTMD) experienced a notable decline in short interest during the month of August, according to recent reports. On August 31st, the total short interest reached 549,400 shares, showing a significant drop of 32.8% from the total on August 15th which stood at 817,700 shares.Instagram:https://instagram. usaa scooter insurancedollar coins 1979best health insurance for contractorsmoneylion direct deposit reviews Feb 9, 2023 · IRVING, Texas--(BUSINESS WIRE)--Feb. 9, 2023-- Biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide fourth quarter and full year financial results on Tuesday, March 28, 2023, after the close of the market. biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. It delivers a comprehensive, end-to-end platform that provides practitioners with medical ... refinance rate wells fargoflorida homeowners insurance increase Get the latest biote Corp (BTMD) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. apple stock prediction Conference Call: Biote management will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET on Wednesday, November 8, 2023. To access the conference call by telephone, please dial (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). To access a live webcast of the call, interested ...A high-level overview of biote Corp. (BTMD) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.